publication date: Aug. 30, 2014
20140830 - Aug. 30, 2014
August 2014PDF

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

A phase III trial of Arzerra as a maintenance therapy for chronic lymphocytic leukemia met its primary endpoint of extending progression-free survival at an interim analysis.

The study evaluated Arzerra (ofatumumab) maintenance therapy versus no further treatment and observation in patients with relapsed CLL who responded to treatment at relapse.

The independent data monitoring committee did not identify any new safety signals and will continue to monitor patients for safety until all study patients complete therapy.  

Stomach Cancer

TCGA Researchers Discover Stomach Cancer Falls Into Four Distinct Molecular Subtypes

Researchers with The Cancer Genome Atlas Network found that stomach cancers fall into four distinct molecular subtypes.

Previous attempts to examine the clinical characteristics of gastric cancer were hindered by how differently cancer cells can look under a microscope, even when from the same tumor. Researchers say the new classification system can serve as a valuable adjunct to the current pathology classification system, which has two categories: diffuse and intestinal.

The researchers identified the new subgroups through complex statistical analyses of molecular data from 295 tumors. They used six molecular analysis platforms including DNA sequencing, RNA sequencing, and protein arrays. The study was published in Nature.

Breast Cancer

Researchers Find Two Types Of MCL Drug Resistance
Human Papillomavirus
International Working Group Suggests Earlier Endpoints For HPV Vaccine Trials
Multiple Myeloma
Phase III Kyprolis Trial Fails OS Primary Endpoint
Kidney Cancer
Researchers Plan to Extend Phase IIa Asonep Trial
Smoking & Survivorship
Study: Nine Years After Diagnosis 9.3% of Survivors Still Smoke
NCI CTEP-Approved Trials for the Month of August
FDA Approvals

  • Avastin combination approved for late-stage cervical cancer

  • FDA approves Cologuard screening test; CMS proposes national coverage determination

  • Health Canada approves Abraxane for first-line treatment of metastatic pancreatic cancer

  • European Medicines Agency approves request for accelerated assessment of lenvatini

  • Sanofi US launches generic Eloxatin

Copyright (c) 2020 The Cancer Letter Inc.